GLP-1 receptor agonists have rapidly emerged as one of the most significant pharmacological developments in weight management. Originally developed for type 2 diabetes, these medications have demonstrated remarkable efficacy in reducing body weight across diverse patient populations — including, increasingly, those experiencing weight gain as a side effect of psychiatric medications.
How GLP-1 Receptor Agonists Work
GLP-1 (glucagon-like peptide-1) is a naturally occurring incretin hormone released by the small intestine after eating. It plays a central role in glucose homeostasis by stimulating insulin secretion, suppressing glucagon release, and slowing gastric emptying. GLP-1 receptor agonists mimic this hormone but resist the rapid enzymatic degradation that limits native GLP-1 to a half-life of just two minutes.
The weight loss effects of GLP-1 agonists operate through multiple pathways. Research published in Nature Reviews Endocrinology has shown these drugs act on hypothalamic appetite centres to reduce hunger signalling, decrease caloric intake by 20–30%, and improve satiety after meals. This multi-mechanism approach distinguishes them from earlier weight loss medications that typically targeted only a single pathway.
Tirzepatide: The Dual-Action Approach
Tirzepatide represents a significant evolution in the GLP-1 class. Unlike earlier single-receptor agonists such as semaglutide and liraglutide, tirzepatide simultaneously activates both the GLP-1 and GIP (glucose-dependent insulinotropic polypeptide) receptors. This dual-agonist mechanism produces more pronounced effects on appetite suppression, insulin sensitivity, and fat metabolism.
The landmark SURMOUNT clinical trial programme evaluated tirzepatide across multiple doses and patient populations. Results published in the New England Journal of Medicine reported average weight reductions of 15% to 20.9% of body weight over 72 weeks, depending on dosage. At the highest dose (15mg), more than one-third of participants achieved weight loss exceeding 25% — results that were described by the study authors as unprecedented for a pharmacological intervention.
Regulatory Status in Australia
In Australia, access to GLP-1 medications is regulated through the Therapeutic Goods Administration (TGA). Semaglutide (marketed as Wegovy for weight management and Ozempic for diabetes) received TGA approval in 2022, while tirzepatide (Mounjaro) was approved for type 2 diabetes management. The Pharmaceutical Benefits Scheme (PBS) currently subsidises certain GLP-1 medications for eligible patients with type 2 diabetes, though access for weight management indications remains largely through private prescriptions.
The TGA’s evaluation of tirzepatide for chronic weight management is ongoing, with healthcare professionals and patients closely following developments. A comprehensive review by the Cochrane Database of Systematic Reviews has provided additional independent assessment of the evidence base supporting GLP-1 agonists for obesity treatment.
Psychiatric Medication and Weight Gain: The Clinical Challenge
Weight gain is one of the most commonly reported side effects of psychiatric medications, affecting up to 72% of patients on certain antipsychotic drugs according to research published in Lancet Psychiatry. SSRIs, SNRIs, mood stabilisers, and atypical antipsychotics can all contribute to metabolic changes that promote fat accumulation through mechanisms including increased appetite, altered insulin signalling, and reduced basal metabolic rate.
For patients being treated for PTSD, this presents a particular clinical dilemma. Discontinuing effective psychiatric treatment to avoid weight gain carries significant mental health risks, yet the metabolic consequences of sustained weight gain — including increased cardiovascular risk, insulin resistance, and worsening of co-morbid conditions — create their own health burden. Emerging research into GLP-1 agonists as an adjunctive therapy for medication-induced weight gain has shown promising early results. Resources that compare tirzepatide options for this population are becoming more widely available, though larger randomised controlled trials are still needed to establish definitive clinical guidelines.
Beyond Weight Loss: Broader Clinical Benefits
The clinical evidence for GLP-1 agonists extends well beyond weight reduction. The SELECT cardiovascular outcomes trial, published in the New England Journal of Medicine, demonstrated a 20% reduction in major adverse cardiovascular events among patients with obesity treated with semaglutide compared to placebo. Participants also showed improvements in systolic blood pressure, waist circumference, C-reactive protein levels, and lipid profiles.
Additional research has identified potential neuroprotective, hepatoprotective, and anti-inflammatory properties of GLP-1 receptor agonists. Studies in The Lancet have explored their application in metabolic dysfunction-associated steatotic liver disease (MASLD), while preclinical evidence suggests potential benefits in neurodegenerative conditions, an area of active investigation.
Looking Ahead
The GLP-1 field continues to evolve rapidly. Next-generation triple-agonist molecules targeting GLP-1, GIP, and glucagon receptors simultaneously are in late-stage clinical trials, with early data suggesting even greater efficacy. Oral formulations that could replace weekly injections are also in development, which may significantly improve patient adherence and accessibility.
For Australian patients and clinicians, staying informed about the evolving evidence base is essential. As regulatory pathways continue to develop and real-world outcome data accumulates, GLP-1 receptor agonists are likely to play an increasingly central role in evidence-based approaches to chronic weight management across diverse clinical populations.